Abstract: An apparatus for quantitatively analyzing gas, particularly oxygen, generated in a battery material, particularly a cathode material is provided. The apparatus contains a switching valve and a sampling loop in a pyrolyzer, thereby allowing an EGA method, which was used only for the qualitative analysis of gas generated from a solid sample, to be used for the quantitative analysis of gas generated at a specific temperature when heat is applied by the pyrolyzer in a battery material.

Abstract: The present invention relates to an apparatus for a high-speed analysis of gas samples using gas chromatography comprising: an organic gas analyzing part comprising a switching valve, a column, and a flame ionization detector (FID); and a fixed gas analysis part comprising a plurality of switching valves, three or more columns comprising a column for electrolyte separation, a column for carbon dioxide separation, and a column for separating fixed gas, a pressure controller, and a thermal conductivity detector (TCD), and an analyzing method using the same.

Abstract: Disclosed is an electrolyte comprising a compound having both a sulfonate group and a cyclic carbonate group. The electrolyte forms a more stable and dense SEI layer on the surface of an anode, and thus improves the capacity maintenance characteristics and lifespan characteristics of a battery. Also, disclosed is a compound represented by the following Formula 1, and a method for preparing the same by reacting 4-(hydroxyalkyl)-1,3-dioxolan-2-one with a sulfonyl halide compound: wherein each of R1 and R2 independently represents a C1˜C6 alkylene group optionally containing a C1˜C6 alkyl group or C2˜C6 alkenyl group introduced thereto; R3 is selected from the group consisting of a hydrogen atom, C1˜C20 alkyl group, C3˜C8 cyclic alkyl group, C2˜C6 alkenyl group, halo-substituted alkyl group, phenyl group and benzyl group.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: Disclosed is a lithium secondary battery comprising a cathode, an anode, an electrolyte and a separator, wherein the anode comprises an anode active material having a specific surface area of 3 m2/g or less, and the electrolyte comprises 0.1˜6 parts by weight of a propane sultone-based compound based on 100 parts by weight of the electrolyte. The lithium secondary battery solves the problem of performance degradation caused by the use of an increased amount of a propane sultone-based compound required to form a SEI film on the surface of an anode upon the first charge cycle. Also, the lithium secondary battery can provide improved cycle characteristics and high-temperature storage characteristics.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: Disclosed is an electrolyte comprising a compound having both a sulfonate group and a cyclic carbonate group. The electrolyte forms a more stable and dense SEI layer on the surface of an anode, and thus improves the capacity maintenance characteristics and lifespan characteristics of a battery. Also, disclosed is a compound represented by the following Formula 1, and a method for preparing the same by reacting 4-(hydroxyalkyl)-1,3-dioxolan-2-one with a sulfonyl halide compound: wherein each of R1 and R2 independently represents a C1˜C6 alkylene group optionally containing a C1˜C6 alkyl group or C2˜C6 alkenyl group introduced thereto; R3 is selected from the group consisting of a hydrogen atom, C1˜C20 alkyl group, C3˜C8 cyclic alkyl group, C2˜C6 alkenyl group, halo-substituted alkyl group, phenyl group and benzyl group.

Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: The present invention relates to novel imidazole derivatives which show an inhibitory activity against farnesyl transferase, pharmaceutically acceptable salts or isomers thereof and pharmaceutical compositions comprising such imidazole derivatives. More particularly, the present invention relates to intermediate compounds which are used in the preparation of the imidazole derivatives of the invention. Related processes also are disclosed.

Abstract: The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n1 and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1): and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Abstract: The present invention relates to novel imidazole derivatives which show an inhibitory activity against farnesyl transferase, pharmaceutically acceptable salts or isomers thereof and pharmaceutical compositions comprising such imidazole derivatives. More particularly, the present invention relates to intermediate compounds which are used in the preparation of the imidazole derivatives of the invention. Related processes also are disclosed.

Abstract: The present invention relates to a novel piperidine derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts thereof, in which A, E and G are defined in the specification; to a process for preparation of the compound of formula (1); to an intermediate which is used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.